A transdermal formulation comprising trazodone or pharmaceutically acceptable salt thereof
A transdermal formulation with trazodone hydrochloride in a hydrogel addresses administration challenges by enabling effective skin delivery, suitable for animals and humans, particularly for treating anxiety-related disorders.
Patent Information
- Application Number
- KR1020220061763
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2022-05-20
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-05-20
AI Technical Summary
Administering trazodone hydrochloride, a serotonin antagonist and reuptake inhibitor, is difficult via oral routes for children, the elderly, and animals, leading to adverse reactions and administration challenges.
A transdermal formulation containing trazodone hydrochloride dispersed in a hydrogel with a hydrophilic polymer and a skin penetration enhancer, allowing for skin absorption.
The formulation effectively delivers trazodone hydrochloride through the skin, addressing administration difficulties and providing a new route for treating behavioral disorders in animals like dogs and cats.
Smart Images

Figure 112022053384809-PAT00002_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a transdermal formulation containing trazodone or a pharmaceutically acceptable salt thereof. Specifically, it relates to a transdermal formulation containing trazodone hydrochloride as an active ingredient. Background Technology
[0003] While oral administration is the most common route of drug administration, difficulties exist in this regard for children, the elderly, and patients unable to ingest medication orally. To address this, drugs are typically delivered via alternative routes, such as patches, ointments, and sprays.
[0004] In the case of administering pharmaceuticals to animals, the reality is that voluntary ingestion is difficult; animals typically exhibit adverse reactions, and in severe cases, can even cause harm to animal breeders and healthcare personnel. To address these drawbacks, changing the route of administration for veterinary medicines can bring many advantages.
[0005] A representative example of changing the administration route of veterinary drugs is Kindred Bioscience’s Mirataz® (a treatment for weight loss caused by abnormal appetite loss in cats), which is a successful example of converting an oral medication into a transdermal ointment.
[0006] Meanwhile, trazodone is a representative serotonin antagonist and reuptake inhibitor, and is one of the representative drugs used in the treatment of depression in humans. Trazodone alleviates characteristic depressive symptoms, particularly anxiety, somatization, psychomotor retardation, hypochondria, mood swings, irritability, insomnia, apathy, feelings of fatigue and lack of energy, and depressed mood. Trazodone has proven effective in controlling significant essential tremor, possibly due to its serotonergic action. Furthermore, the antidepressant and anxiolytic properties of trazodone have proven effective in treating withdrawal symptoms from cocaine, benzodiazepines, and alcohol. In addition to the aforementioned actions, its sleep-inducing activity is very impressive. Meanwhile, trazodone is mainly used in the form of salts, specifically primarily provided as hydrochloride.
[0007] Korean Patent Publication No. 10-2008-0047539 discloses a sustained-release formulation containing trazodone hydrochloride.
[0008] Trazodone hydrochloride is widely used in animals for the treatment of mental disorders, most notably for treating anxiety or phobia-related behavioral disorders in dogs (fear of fireworks, thunderstorms, noise, veterinarian visits, hospitalization, etc.). Trazodone hydrochloride is currently used as an oral medication, such as tablets or capsules, for both human and animal use, but there are significant difficulties in administering oral formulations to animals such as dogs.
[0010] Accordingly, the inventors of the present invention made efforts to develop a transdermal absorption formulation that delivers the trazodone hydrochloride through the skin and completed the present invention. The problem to be solved
[0012] One objective of the present invention is to provide a transdermal formulation containing trazodone or a pharmaceutically acceptable salt thereof as an active ingredient.
[0013] Another objective of the present invention is to provide a transdermal formulation comprising trazodone hydrochloride for administration to animals. means of solving the problem
[0015] The present invention comprises trazodone or a pharmaceutically acceptable salt thereof as an active ingredient;
[0016] and includes a hydrogel in which the above active ingredient is dispersed,
[0017] The above hydrogel provides a transdermal absorption formulation comprising 0.1 to 10 weight% of a hydrophilic polymer.
[0018] The above trazodone or a pharmaceutically acceptable salt thereof may be trazodone hydrochloride.
[0019] The above hydrogel may further include a skin penetration enhancer.
[0020] The above hydrogel may contain 5 to 40 weight percent of a skin penetration enhancer.
[0021] The above hydrophilic polymer may include a cellulose-based polymer.
[0022] The above-mentioned transdermal formulation may be used for the prevention or treatment of behavioral disorders related to anxiety or phobia, and may be intended for dogs or cats. Effects of the invention
[0024] The transdermal absorption formulation according to the present invention can deliver the active ingredient, trazodone hydrochloride, into the body by attaching it to the skin, and accordingly, can provide a new formulation that can resolve the difficulties in administering trazodone-containing formulations to pets such as dogs and cats. Brief explanation of the drawing
[0026] Figure 1 shows the results of a transdermal absorption experiment according to Example 1 and a comparative example. Figure 2 shows the results of transdermal absorption experiments according to Examples 2 to 6. Figure 3 shows the results of transdermal absorption experiments according to Examples 7 to 12. Specific details for implementing the invention
[0027] The present invention will be described in detail below.
[0028] Embodiments of the present invention may be modified in various different forms, and the scope of the present invention is not limited to the embodiments described below. Furthermore, embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art. Moreover, throughout the specification, the term "comprising" any component means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.
[0030] One aspect of the present invention is, as an active ingredient, trazodone or a pharmaceutically acceptable salt thereof;
[0031] and includes a hydrogel in which the above active ingredient is dispersed,
[0032] The above hydrogel provides a transdermal absorption formulation comprising 0.1 to 10 weight% of a hydrophilic polymer.
[0034] Trazodone has the structure of the following chemical formula 1 and has the IUPAC name (2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one).
[0035] [Chemical Formula 1]
[0036]
[0038] Since trazodone was first approved for medicinal use in the United States in 1981, it has been widely prescribed to humans as a treatment for depression. In the present invention, the trazodone may be used in the form of a hydrochloride, but is not limited thereto.
[0039] The content of the above active ingredient is not particularly limited, but it must exist in a dissolved state within the hydrogel to enable transdermal absorption. For example, it may be included and dispersed in an amount of 0.1 to 20 weight%, 0.5 to 10 weight%, or 1 to 10 weight% relative to the weight of the hydrogel. The weight of the hydrogel refers to the weight of the matrix composed of a polymer containing water, excluding the active ingredient.
[0041] The compound represented by Formula 1 of the present invention may be used in the form of a pharmaceutically acceptable salt, and the salt may be an acid addition salt formed by a pharmaceutically acceptable free acid. The acid addition salt is obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromide, hydroiodide, nitrous acid, phosphoric acid, etc., aliphatic mono and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates and alkandioates, aromatic acids, aliphatic and aromatic sulfonic acids, etc., non-toxic organic acids such as trifluoroacetic acid, acetate, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, fumaric acid, etc. These types of pharmaceutically non-toxic salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphate chloride, bromides, iodides, fluorides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caprates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, malieates, butyne-1,4-dioate, hexane-1,6-dioate, benzoates, chlorobenzoates, methyl benzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, and phthalates. Includes terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, etc.
[0042] The acid addition salt according to the present invention can be prepared by conventional methods, for example, by dissolving a derivative of Formula 1 in an organic solvent such as methanol, ethanol, acetone, methylene chloride, acetonitrile, etc., adding an organic acid or an inorganic acid to produce a precipitate, filtering and drying it, or by vacuum distilling the solvent and excess acid, drying it, and crystallizing it under an organic solvent.
[0044] Hydrogels, also known as hydrated gels, refer to semi-solid gels containing water, as the name suggests. Since these polymers do not completely dissolve in water through a three-dimensional cross-linking structure and can contain a significant amount of water within the cross-linking structure, they are widely utilized in wound healing agents and the like. To manufacture hydrogels, polymers with water affinity, such as hydrophilic or water-soluble polymers, are used. Examples include cellulose-based polymers, (meth)acrylic acid or (meth)acrylate-based polymers, acrylamide-based polymers, chitosan polymers, hyaluronic acid polymers, polyethylene glycol polymers, and alginate polymers; preferably, cellulose-based polymers are used. Cellulose-based polymers are used as excipients in various formulation forms of pharmaceutical preparations, and are widely used as excipients in tablets.
[0045] As the above cellulose-based polymer, one or more selected from hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, methylcellulose, and ethylcellulose may be used. In the present invention, hydroxypropyl methylcellulose (HPMC) was used as a specific example, but is not limited thereto and other cellulose-based polymers approved for pharmaceutical use may also be used.
[0046] It is evident that the content of the polymer forming the hydrogel requires a moisture medium that has mechanical strength suitable for application to the skin, is sufficient to dissolve trazodone or its salts included as active ingredients, and allows the active ingredients to be delivered to the skin through diffusion, and that the content of the polymer may vary depending on the type of polymer and the content of the active ingredients.
[0047] A person skilled in the art can form a hydrogel by appropriately adjusting the polymer content according to the selected polymer, and depending on the type of polymer, a metal ion can be used as a crosslinking agent to form the hydrogel, or an acid or base can be added to adjust pH conditions for crosslinking to form the hydrogel.
[0048] For example, the content of the cellulose-based polymer is not particularly limited, but in order to form a stable hydrogel, the content may be included in an amount of 0.1 to 10 weight%, 0.5 to 5 weight%, or 0.5 to 1.5 weight% based on the total weight of the hydrogel.
[0050] Meanwhile, the remainder of the hydrogel excluding the polymer may include water.
[0051] The water content of the hydrogel can be adjusted to have strength and viscosity suitable for application to the skin, and can be appropriately selected depending on the type of hydrophilic polymer and the content of the active ingredient, for example, it can be 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more based on the total weight of the hydrogel, and the upper limit can be 99.9%, 99%, or 90% or less.
[0052] Meanwhile, the hydrogel may further include a skin penetration enhancer to promote the skin penetration of trazodone or a pharmaceutically acceptable salt thereof as an active ingredient. Any known skin penetration enhancer may be used, but, for example, both aqueous and oil-based skin penetration enhancers may be used.
[0054] As a skin penetration enhancer, it may comprise one or more selected from propylene glycol, isopropyl myristate, and diethylene glycol monoethyl ether (transcutol HP as a product), preferably propylene glycol, but is not limited thereto.
[0055] The skin permeability enhancer may be included in an amount of 5 to 40 weight%, 5 to 30 weight%, 5 to 20 weight%, 10 to 30 weight%, 5 to 15 weight%, or 7 to 13 weight% based on the total weight of the hydrogel. Alternatively, the volume ratio of water to skin permeability enhancer with respect to the water contained in the hydrogel may be selected from a ratio of 99:1 to 50:50 or 95:5 to 65:35.
[0057] The above hydrogel may further include other pharmaceutically acceptable additives. It may further include thickeners, antioxidants, pH adjusters, etc.
[0058] Since the hydrophilic polymer that forms the hydrogel itself can act as a thickener, the hydrophilic polymer itself may be added as a thickener. The thickener can increase the strength of the hydrogel and maintain the shape of the hydrogel, thereby increasing the convenience of application and allowing it to remain on the skin during the delivery of the active ingredient after application.
[0060] The above transdermal absorption formulation may further include a support for supporting the hydrogel as needed. The support may further include a polymer film, nonwoven fabric, etc. that supports the hydrogel, and may employ various materials known in the field.
[0061] The above transdermal formulation can be applied to mammals, including humans.
[0062] The above-mentioned transdermal formulation may be a veterinary medicine, and as a specific example of application, it may be a veterinary medicine intended for application to pets such as dogs or cats. The above-mentioned transdermal formulation may be applied as a topical skin preparation by directly applying it to the skin of the subject. The above-mentioned transdermal formulation may be used for the prevention or treatment of behavioral disorders related to depression, anxiety, or phobias. It may be administered for the purpose of calming an excited state in animals.
[0063] In another aspect, the present invention may provide a method for calming excitement in a mammal, comprising the step of applying the transdermal formulation to the skin of the mammal.
[0065] Specific embodiments are presented below to aid in understanding the invention. The following embodiments are provided merely to facilitate a better understanding of the invention and do not limit the scope of protection of the invention to the following embodiments.
[0067] Example 1. Preparation of Hydrogel
[0068] 400 mg of trazodone hydrochloride was accurately weighed and completely dissolved in 20 ml of purified water, and then 4,000 cps of hydroxypropyl methylcellulose (HPMC) was dissolved in 200 mg of the drug solution to prepare a hydrogel containing a polymer at a concentration of 1% w / v.
[0070] Examples 2 to 6. Preparation of hydrogels containing a skin penetration enhancer
[0071] After mixing each type of skin penetration enhancer with purified water in a certain ratio, 400 mg of trazodone hydrochloride was accurately weighed and added to 20 ml of the mixture to be completely dissolved, and then 200 mg of HPMC 15,000 cps was dissolved in the drug solution to prepare a hydrogel at a concentration of 1% w / v.
[0073] Types of permeability enhancers Permeation enhancer ratio (volume %) in the mixture with distilled water Example 2. Propylene glycol 10 Example 3. Isopropyl myristate 10 Example 4. Isopropyl myristate 20 Example 5. Propylene glycol + Isopropyl myristate 20 (10 each) Example 6. Propylene glycol + Transcutol HP 20 (10 each)
[0075] Examples 7 to 12.
[0076] A hydrogel was prepared as in Example 2, but with the ratios shown in Table 2 below.
[0077] HPMC Ratio (Weight relative to volume of distilled water and propylene glycol, % w / v) Propylene glycol ratio (volume %) relative to the mixture with distilled water Example 7. 1 20 Example 8. 1 30 Example 9. 2 20 Example 10. 2 30 Example 11. 3 20 Example 12. 3 30
[0079] Examples 13. Carbomer used hydrogel's manufacturing
[0080] Carbomer 940 was accurately weighed at 1 g and completely dissolved in 100 ml of purified water, then neutralized with a 25% sodium hydroxide solution to create gel properties, and then a certain amount of trazodone hydrochloride was added and mixed to prepare a carbomer hydrogel.
[0082] Comparative Example 1. Trazodone hydrochloride-containing ointment formulation
[0083] 4g of white Vaseline was accurately weighed and completely melted in a water bath of boiling water. Then, 250mg of glycerin stearic acid, 250mg of funnel oil, and 500mg of trazodone hydrochloride were added, and the mixture was uniformly mixed using a homogenizer (13,000 RPM, 5 minutes). Afterward, the mixture was removed from the water bath, allowed to cool to room temperature, and mixed consistently using a mixer to prepare the trazodone ointment.
[0085] Comparative Example 2. Trazodone hydrochloride-containing ointment formulation
[0086] To prepare trazodone emulsions, trazodone emulsions were prepared by varying the ratio of surfactant mixtures, oil mixtures, and purified water using surfactants and combinations thereof.
[0087] As a surfactant mixture, Labrasol and Transcutol P were mixed in a 1:1 volume ratio, and as an oil mixture, Capryol 90 and Funnel oil were mixed in a 1:1 volume ratio.
[0088] We checked whether an emulsion was formed after mixing oil mixtures with different ratios of surfactant mixture and purified water.
[0089] Subsequently, a clear and transparent emulsion solution was selected and used for transdermal absorption experiments. The emulsion solution used was prepared by mixing a surfactant mixture and an oil mixture in a ratio of 7:3, and by mixing the surfactant mixture and the oil mixture in a ratio of 7:3 to purified water in a ratio of 6:4.
[0091] Experimental Example 1. Transdermal absorption experiment
[0092] 1) Experimental Method
[0093] Transdermal absorption experiments were conducted using a Franz diffusion cell.
[0094] Permeable membrane: skin of hairless mouse, etc.
[0095] Test solution: Phosphate buffer saline pH 7.4 solution
[0096] RPM: 400 RPM
[0097] Temperature: 37 ± 0.5℃
[0098] Sampling time: 5 min, 10 min, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 6 hours, 24 hours
[0099] For the penetration test, 1.0 mL of hydrogel was applied to an area of 1.76 cm², and 20 mg of drug was applied to each area.
[0100] Skin penetration tests were conducted on comparative examples and examples under the above conditions.
[0102] 2) Experimental Results 1
[0103] As a result of conducting permeability tests on the ointment (Comparative Example 1), emulsion solution (Comparative Example 2), and the hydrogel of Example 1, as shown in Figure 1, it was confirmed that in the case of the ointment, a small amount was permeated at half the level compared to the hydrogel. In the case of the emulsion solution, it was confirmed that no permeation occurred for 24 hours, confirming that the hydrogel formulation is suitable as a trazodone hydrochloride skin permeability formulation.
[0105] 3) Experimental Results 2
[0106] It is shown in Fig. 2.
[0107] When a permeability enhancer was included, it showed a higher permeability pattern than Example 1, and was particularly effective in allowing the drug to permeate from the time of application until the first 6 hours.
[0108] Among them, the hydrogel with added propylene glycol (Example 2) had the highest permeability and allowed permeability up to 6 hours, and the permeability increased even more after 6 hours.
[0109] In the case of isopropyl myristate (Example 3), it enabled permeability in the early time period, although lower than that of propylene glycol.
[0110] On the other hand, when other promoters were mixed with propylene glycol, the permeability was not higher than when propylene glycol was used alone.
[0112] 4) Experimental Results 3
[0113] The permeation test results of Examples 7 to 12, in which the polymer content or the propylene glycol content was varied, are as shown in Fig. 3.
[0114] It exhibits a higher permeability compared to Example 1, which does not contain propylene glycol.
[0116] Through the above examples and experimental examples, it was confirmed that the hydrogel according to the present invention is an effective formulation for the transdermal absorption of trazodone or its hydrochloride.
Claims
Claim 1 A transdermal absorption formulation comprising: trazodone hydrochloride as an active ingredient; and a hydrogel in which said active ingredient is dispersed, wherein said active ingredient exists in a state dissolved in water within the hydrogel, said hydrogel comprises HPMC, a cellulose-based polymer, propylene glycol, a skin penetration enhancer, and water, said HPMC is 0.5 to 5 weight% based on the total weight of the hydrogel excluding the active ingredient, said propylene glycol is 5 to 15 weight% based on the total weight of the hydrogel excluding the active ingredient, said water is 70 to 90 weight% based on the total weight of the hydrogel excluding the active ingredient, and said trazodone hydrochloride is contained in an amount of 0.1 to 20 weight% based on the total weight of the hydrogel. Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 delete Claim 7 delete Claim 8 In claim 1, the transdermal formulation is a transdermal formulation for the prevention or treatment of behavioral disorders related to anxiety or phobia. Claim 9 In claim 1, the transdermal absorption formulation is a transdermal absorption formulation intended for dogs or cats.
Citation Information
Patent Citations
Hydrogel composition for transdermal drug
KR1020020002199A
Compositions and methods to effect the release profile in the transdermal administration of active agents
US20020004065A1
